EHA 2026 highlights include advances in immunotherapy across blood cancers.
Rahul Banerjee, MD
Advertisement
Rahul Banerjee, MD, is an assistant professor at the Fred Hutchinson Cancer Center.
Articles by Rahul Banerjee, MD
In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD
3
Integrated VA Care Linked to Equitable Cancer Survival for Black Veterans
4
Pediatric Cancer Carries Greater Financial Toxicity Than Adult Disease, Driving Calls for Systemic Change
5